Press Releases

Breadcrumb

Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Confirms Commencement of Voluntary Liquidation
VANCOUVER, British Columbia , Jan. 16, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) today announced that the implementation of the Company’s voluntary liquidation (the “Liquidation”) commenced at 5:00 p.m. Pacific Time today, January 16, 2020 (the “Effective
View HTML
Toggle Summary Novelion Therapeutics Announces January 16, 2020 Effective Date for Commencement of Voluntary Liquidation
VANCOUVER, British Columbia , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced the definitive date for commencement of implementation of the Company’s voluntary liquidation (the “Liquidation”) as 5:00 p.m.
View HTML
Toggle Summary Novelion Therapeutics Provides Updates on Voluntary Liquidation and Other Matters
VANCOUVER, British Columbia , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today provided updates on the status of the Company’s voluntary liquidation and other matters. Background on Company Liquidation As previously announced, at the
View HTML
Toggle Summary Novelion Therapeutics Provides Update on Effective Date of Liquidation
VANCOUVER, British Columbia , Dec. 11, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced that a hearing date has not yet been scheduled for consideration of the Company’s application materials, filed on November 18, 2019 with the
View HTML
Toggle Summary Novelion Therapeutics Provides Updates on Voluntary Liquidation and Other Matters
VANCOUVER, British Columbia , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today provided updates on the status of the Company’s voluntary liquidation and other matters. Background on Company Liquidation As previously announced, at the
View HTML
Toggle Summary Novelion Therapeutics Announces Results of 2019 Annual General Meeting of Shareholders
Shareholders Approve All Company Proposals, Including Voluntary Liquidation and Dissolution of the Company VANCOUVER, British Columbia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced the results of its 2019 Annual General
View HTML
Toggle Summary Novelion Therapeutics Announces New Trading Symbol
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) announced that, effective as of the opening of business today, its common shares have commenced trading under the symbol “NVLNF” on an
View HTML
Toggle Summary Novelion Therapeutics Announces Nasdaq Delisting
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (the “Panel”) has
View HTML
Toggle Summary Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable securities regulatory authorities
View HTML
Toggle Summary Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019 , the acquisition by Amryt Pharma Plc (“Amryt”) of 100% of the
View HTML